Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$12.32 USD
-0.51 (-3.98%)
Updated May 30, 2024 04:00 PM ET
After-Market: $12.31 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Kyverna Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 58 | 51 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 3 | 2 | NA | NA | NA |
Total Current Assets | 61 | 53 | NA | NA | NA |
Net Property & Equipment | 2 | 3 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 6 | 3 | NA | NA | NA |
Total Assets | 75 | 67 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 4 | 1 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 1 | 1 | NA | NA | NA |
Accrued Expenses | 9 | 8 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 4 | 1 | NA | NA | NA |
Total Current Liabilities | 20 | 12 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 1 | 1 | NA | NA | NA |
Other Non-Current Liabilities | 181 | 121 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 207 | 141 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 5 | 2 | NA | NA | NA |
Retained Earnings | -136 | -76 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | -131 | -74 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 75 | 67 | NA | NA | NA |
Total Common Equity | -131 | -74 | 0 | 0 | 0 |
Shares Outstanding | NA | NA | NA | NA | NA |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Kyverna Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 370 | 58 | -99,999 | -99,999 | 0 |
Receivables | 0 | 0 | NA | NA | 0 |
Notes Receivable | 0 | 0 | NA | NA | 0 |
Inventories | 0 | 0 | NA | NA | 0 |
Other Current Assets | 6 | 3 | NA | NA | 0 |
Total Current Assets | 375 | 61 | NA | NA | 0 |
Net Property & Equipment | 3 | 2 | NA | NA | 0 |
Investments & Advances | 0 | 0 | NA | NA | 0 |
Other Non-Current Assets | 0 | 0 | NA | NA | 0 |
Deferred Charges | 0 | 0 | NA | NA | 0 |
Intangibles | 0 | 0 | NA | NA | 0 |
Deposits & Other Assets | 3 | 6 | NA | NA | 0 |
Total Assets | 390 | 75 | NA | NA | 0 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | 0 |
Accounts Payable | 7 | 4 | NA | NA | 0 |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | 0 |
Current Portion Capital Leases | 1 | 1 | NA | NA | 0 |
Accrued Expenses | 8 | 9 | NA | NA | 0 |
Income Taxes Payable | 0 | 0 | NA | NA | 0 |
Other Current Liabilities | 3 | 4 | NA | NA | 0 |
Total Current Liabilities | 22 | 20 | NA | NA | 0 |
Mortgages | 0 | 0 | NA | NA | 0 |
Deferred Taxes/Income | 0 | 0 | NA | NA | 0 |
Convertible Debt | 0 | 0 | NA | NA | 0 |
Long-Term Debt | 0 | 0 | NA | NA | 0 |
Non-Current Capital Leases | 1 | 1 | NA | NA | 0 |
Other Non-Current Liabilities | 0 | NA | NA | 0 | |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | 0 |
Total Liabilities | 29 | 207 | NA | NA | 0 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | 0 |
Common Stock (Par) | 0 | 0 | NA | NA | 0 |
Capital Surplus | 524 | 5 | NA | NA | 0 |
Retained Earnings | -163 | -136 | NA | NA | 0 |
Other Equity | 0 | 0 | NA | NA | 0 |
Treasury Stock | 0 | 0 | NA | NA | 0 |
Total Shareholder's Equity | 361 | -131 | NA | NA | 0 |
Total Liabilities & Shareholder's Equity | 390 | 75 | NA | NA | 0 |
Total Common Equity | 361 | -131 | 0 | 0 | 0 |
Shares Outstanding | 43.10 | NA | NA | NA | NA |
Book Value Per Share | 8.38 | 0.00 | 0.00 | 0.00 | 0.00 |